ARTICLE | Company News
EMA to review Krystexxa for gout
May 27, 2011 12:32 AM UTC
EMA accepted for review an MAA from Savient Pharmaceuticals Inc. (NASDAQ:SVNT) for Krystexxa pegloticase to treat chronic gout in patients refractory to conventional therapy. The pegylated urate oxida...